Taro Pharmaceutical Industries Ltd.

NYSE:TARO Stock Report

Market Cap: US$1.6b

Taro Pharmaceutical Industries Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Uday Baldota

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.7yrs
CEO ownershipn/a
Management average tenure8.6yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03
We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

CEO

Uday Baldota (53 yo)

6.7yrs

Tenure

Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...


Leadership Team

NamePositionTenureCompensationOwnership
Uday Baldota
CEO & Director6.7yrsno datano data
William Coote
VP, CFO & Chief Accounting Officer2.3yrsno datano data
Itamar Karsenti
VP & Head of Operations9.3yrsno datano data
Avi Avramoff
VP and Head of R&D12.5yrsno datano data
Itzik Baruch
Vice President of Technical Services14.3yrsno datano data
Roman Kaplan
Vice President of Scientific and Technical Compliance Managerno datano datano data
Erik Zwicker
VP, General Counsel & Secretary4yrsno datano data
Ara Aprahamian
Vice President of Sales & Marketing11.1yrsUS$616.14kno data
Michele Visosky
VP & Head of Human Resourceno datano datano data
Jayesh Shah
Head of Procurement12.3yrsno datano data
Richard Glaze
VP & Head of Information Technology7.8yrsno datano data
Ori Gutwerg
VP & Head of U.S. Generics Rx5yrsno datano data

8.6yrs

Average Tenure

57yo

Average Age

Experienced Management: TARO's management team is seasoned and experienced (8.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Uday Baldota
CEO & Director7.3yrsno datano data
Dilip Shanghvi
Chairman of the Board10.8yrsUS$1.00mno data
Robert Stein
Independent Director4.2yrsno datano data
Sudhir Valia
Director13.6yrsUS$500.00kno data
James Kedrowski
Director12.9yrsno datano data
Linda Shushan
Independent Director7.3yrsno datano data
Abhay Gandhi
Vice Chairman7.3yrsno datano data
Oded Sarig
Independent Directorless than a yearno datano data

7.3yrs

Average Tenure

67yo

Average Age

Experienced Board: TARO's board of directors are considered experienced (7.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.